Tharimmune, Inc.
NASDAQ: THAR0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mark Wendland
- Employees
- 2
- Headquarters
- Bridgewater, United States
- IPO year
- 2022
- Market cap
- $139.9M
- Website
- https://www.tharimmune.com
Loading THAR…
Loading profile data…Frequently asked questions about THAR
What does Tharimmune, Inc. (THAR) do?
Tharimmune, Inc. is a biotechnology firm operating in the clinical stage, focused on creating therapeutic solutions for rare, inflammatory, and oncological conditions. Its preclinical immuno-oncology portfolio includes several product candidates: TH104, aimed at treating inflammatory conditions linked to the liver and other causes of itching; TH...
Where does THAR trade?
Tharimmune, Inc. (THAR) trades on the NASDAQ Capital Market.
What sector is THAR in?
Tharimmune, Inc. (THAR) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Tharimmune, Inc.?
Mark Wendland is the chief executive officer of Tharimmune, Inc. (THAR).
Where is Tharimmune, Inc. headquartered?
Tharimmune, Inc. is headquartered in United States.
Does THAR pay a dividend?
Tharimmune, Inc. (THAR) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did THAR go public?
Tharimmune, Inc. (THAR) completed its initial public offering in 2022.